TOPIX review affects mid-sized pharmaceutical companies and wholesalers; Oncolys and GNI newly added | Nikkan Yakugyo - Comprehensive Information Site for the Pharmaceutical Industry

Japan Exchange Group's TOPIX review is expected to affect mid-sized pharmaceutical companies and drug wholesalers, with Oncolys and GNI cited as new additions.

Read in fullFrom the source, not the headline

sources corroborateOutlets reporting the same event

companies linkedAcross 0 themes, second pass

The story

The TOPIX review is expected to affect companies in sectors including pharmaceuticals and drug wholesaling. This article highlights mid-sized pharmaceutical companies and wholesalers as among those affected by the review.

Oncolys and GNI are cited as new additions, with the direction of the TOPIX review and the resulting changes in index constituents the focus.

At a glance

EventTOPIX review to affect mid-sized pharmaceutical companies and drug wholesalers

New additionsOncolys and GNI identified as new additions

SourceJapan Exchange Group's TOPIX review

Reference information. Every claim resolves to something the story actually named.

Where this came from

We read each source in full and checked they agree on the core claim.

1/ 1 agree

All of them report the same thing.

nk.jiho.jpNews

PrimaryOpen

Read the original articleGo to the source page

Reference information generated from public sources. It does not solicit or advise on investments. Prices are 15-minute delayed.